All News

Found 232 articles

• Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

  12/16/2021

  Kura Oncology, Inc. (Nasdaq: KURA), today announced dose administration for the first patient in KURRENT, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).

• Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

  12/13/2021

  Kura Oncology, Inc. (Nasdaq: KURA), today announced final results from a Phase 2 study of tipifarnib as a monotherapy in patients with relapsed or refractory T-cell lymphoma, including an overall response rate (ORR) of 56% and a median overall survival of 32.8 months in heavily pretreated patients with angioimmunoblastic T-cell lymphoma (AITL).

• Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax

  12/13/2021

  Kura Oncology, Inc. announced the presentation of new preclinical data for KO-539, the Company’s oral, potent and selective menin inhibitor, and its potential for synergistic activity in combination with venetoclax, a current standard of care in the treatment of patients with acute myeloid leukemia.

• 

  Clinical Catch-Up: November 22-26

  11/29/2021

  Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
• 

  AML Study Placed Under Partial Hold Following Patient Death

  11/24/2021

  Shares of Kura Oncology have plunged nearly 30% in premarket trading after the FDA placed a partial clinical hold on the company’s Phase Ib leukemia study following the report of a patient's death.

• Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

  11/24/2021

  Kura Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold.

• Kura Oncology to Participate in Two Upcoming Investor Conferences - Nov 23, 2021

  11/23/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences.

• Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors

  11/18/2021

  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed Bridget Martell, MA, M.D., to the Company’s board of directors.

• Kura Oncology Reports Third Quarter 2021 Financial Results

  11/4/2021

  Kura Oncology, Inc. today reported third quarter 2021 financial results and provided a corporate update.

• Kura Oncology to Participate in Credit Suisse Healthcare Conference

  11/2/2021

  Kura Oncology, Inc. today announced its participation in the Credit Suisse 30th Annual Healthcare Conference.

• Kura Oncology to Report Third Quarter 2021 Financial Results

  10/28/2021

  Kura Oncology, Inc. today announced that it will report third quarter 2021 financial results after the close of U.S. financial markets on Thursday, November 4, 2021.

• 

  BioSpace Movers & Shakers, Oct. 22

  10/22/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer

  10/19/2021

  Artizan Biosciences, Inc., a biotechnology company at the frontier of microbiome precision medicine, announced the appointment of Bridget Martell, M.A., M.D., as President and Chief Executive Officer.

• Kura Oncology Appoints Teresa Bair as Chief Legal Officer

  10/18/2021

  Kura Oncology, Inc. today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate Secretary.

• ReForm Biologics Bolsters Diversity With New Appointments to Board of Directors

  9/21/2021

  ReForm Biologics, Inc., a company developing a new generation of innovative biologic medicines to improve patient access, safety, and convenience, announced the appointment of four new Directors with significant life science and biotechnology experience: Roopom Banerjee, Kirsten Flowers, Stuart Randle and Edward Sullivan.

• Kura Oncology to Participate in Two Upcoming September 2021 Investor Conferences

  9/7/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences.

• 

  BioSpace Movers & Shakers: Sept. 3

  9/3/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• PepGen Announces New Additions to Leadership Team and Board of Directors

  8/31/2021

  PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, announced that Heidi Henson will join PepGen’s Board of Directors.

• CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

  8/24/2021

  CTI BioPharma Corp. announced the appointment of Diane Parks to its Board of Directors.

• Kura Oncology Reports Second Quarter 2021 Financial Results

  8/5/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported second quarter 2021 financial results and provided a corporate update.